Exscientia to collaborate with Oxford's Alzheimer's center; Dana-Farber enlists Repertoire for head and neck cancer
The AI outfit Exscientia has forged a collaboration with the Alzheimer’s Research UK University of Oxford Drug Discovery Institute to develop new drugs aimed at taming the memory-wasting ailment by targeting neuroinflammation.
The partners highlighted the inflammatory role of NLRP3 in their statement, highlighting an inflammasome that has inspired a few startups in recent years.
They’ll be working together to screen new drug candidates, looking for a breakthrough in a field that so far has frustrated virtually every developer which has given it a try in the last 20 years or so.
“We are delighted to be partnering with Exscientia,” said John Davis, CSO of the institute. “Their state-of-the-art AI capabilities will enable us to investigate multiple molecules in parallel and accelerate the project towards candidate declaration. Human genetic variation points towards a critical role for the body’s immune system in an individual’s risk of developing Alzheimer’s disease. It is vital that we develop treatments that target neuroinflammatory mechanisms underlying dementia.” — John Carroll
Repertoire and Dana-Farber join forces in head and neck cancers
Repertoire Immune Medicines has a new partner in its quest to identify new tumor antigen targets.
The Cambridge, MA-based biotech will work with the Dana-Farber Institute in a collaboration to advance development for HPV+ head and neck cancer treatments. The pair will aim to find new targets for the cancers that can help inform such treatments’ development.
Thursday’s deal will pair Dana-Farber’s expertise and supply of blood and tissue samples from patients with Repertoire’s platform that seeks to identify the antigens. Repertoire is looking to glean information that can be used in T cell therapies.
“While many with human papillomavirus (HPV)-positive oropharyngeal cancer are cured, there remains an urgent need for new treatments among those with recurrent or incurable disease,” said Glenn Hanna, Dana-Farber’s director of salivary, head and neck cancer center, in a statement.
It marks the second partnership between the two, as Dana-Farber is currently helping run a Phase I study for Repertoire’s IL-15 drug candidate. — Max Gelman